Latest filing published 06 Apr 2022 for Tissue Regenix Group plc, €9,417.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
David Cocke: trading record in brief
David Cocke discloses dealings in Tissue Regenix Group plc to RNS (LSE). In total, 3 filings cover trades dated from 7 May 2021 to 5 April 2022.
Purchases make up the whole of the open-market record (3 purchases, €39k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2022, the count stands at 1 purchase and no sales.
The median purchase comes to €9,417. 1 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
On 6 April 2022 came the latest disclosure, an open-market purchase for €9,417 in Tissue Regenix Group plc. Filings reach the RNS (LSE) feed a median of 1 day after the trade. The regulation allows three business days to notify a trade (UK MAR). Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to David Cocke
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,785,000 shares@ £0.004424.3% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4330505-1Canonical exit: 4 Jul 2022 (T+90)
- 1,086,000 shares@ £0.006722.0% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4105552Canonical exit: 8 Dec 2021 (T+90)
- 2,821,000 shares@ £0.006453.7% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:3969072Canonical exit: 5 Aug 2021 (T+90)
3 of 3 declarations